[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635647":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":19,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":19,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":75,"whyStopped":19,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Children's Hospital of Fudan University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Decitabine, Route of administration: Intravenous infusion","Participants receive decitabine at a dose of 20 mg\u002Fm² once daily for five consecutive days per treatment cycle. Each dose is administered as a continuous intravenous infusion over at least one hour. Each cycle consists of five doses, and a total of four cycles are planned.",[12],"Drug: Decitabine",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Decitabine","Decitabine 20 mg\u002Fm² intravenous infusion once daily for 5 consecutive days every 4 weeks, for a total of 4 cycles.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Jia Hou, Ph.D., M.D.","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","86-21-64933338","doctorhoujia@hotmail.com",{"name":30,"role":26,"phone":31,"phoneExt":19,"email":32},"Wenjie Wang, M.D.","86-21-64931085","amazingmm@163.com",[34],{"facility":5,"status":19,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Shanghai","Shanghai Municipality","201102","China","CN",{"type":41,"coordinates":42},"Point",[43,44],121.45806,31.22222,{"lat":44,"lon":43},[47,48],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},{"name":30,"role":26,"phone":31,"phoneExt":19,"email":32},{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[52],{"name":53,"class":54},"National Natural Science Foundation of China","OTHER_GOV","100635647","phase-4-evaluating-the-safety-and-efficacy-of-decitabine-in-the-treatment-of-xmen-patients-100635647",false,"NCT07555405","Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients","Single-arm Clinical Study Evaluating the Safety and Efficacy of Decitabine in the Treatment of X-linked MAGT1 Deficiency With Increased Susceptibility to EBV Infection and N-linked Glycosylation Defect (XMEN) Patients","Inclusion Criteria:\n\n1. Male participants aged 1 month to 18 years old.\n2. Confirmed MAGT1 gene mutation by genetic testing.\n3. Clinical manifestations consistent with XMEN disease, including liver dysfunction and\u002For EBV infection.\n4. Reduced lymphocyte NKG2D expression.\n5. Vital signs within normal range at screening.\n6. Expected survival ≥ 6 months.\n7. Able to comply with study procedures.\n8. Guardian and participant provide written informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity to decitabine or any excipient.\n2. Hematopoietic stem cell transplantation within 1 year before enrollment.\n3. Severe concurrent organ dysfunction or systemic disease.\n4. Positive HBsAg, anti-HCV, syphilis, or HIV test.\n5. Neurological or psychiatric disorders that impair compliance.\n6. Participation in another clinical trial within 3 months.\n7. Other conditions judged inappropriate by the investigator.","MALE","1 Month","18 Years",{"count":66,"type":67},6,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","This is a single-arm, open-label, single-center, exploratory clinical trial evaluating the safety and efficacy of decitabine in male patients aged 1 month to 18 years with X-linked magnesium transporter 1 (MAGT1) deficiency. Eligible patients have a confirmed MAGT1 gene mutation leading to XMEN disease ( X-linked MAGT1 deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect). The study will assess changes in liver function, immune function, and NKG2D expression, as well as adverse events, over four treatment cycles and the follow-up period.",[73],"MAGT1 Deficiency",[16],"NOT_YET_RECRUITING","2026-04-24",{"date":78,"type":79},"2026-04-29","ACTUAL",{"date":81,"type":67},"2026-04",{"date":83,"type":67},"2028-12",{"name":5,"class":6},1]